Literature DB >> 22622628

Anxiety and methylphenidate in attention deficit hyperactivity disorder: a double-blind placebo-drug trial.

Keren Moshe1, Avi Karni, Emanuel Tirosh.   

Abstract

To examine the relationship between attention and anxiety and the response to methylphenidate in children with attention deficit hyperactivity disorder (ADHD), a total of 57 boys, between the ages of 7-12 years, were assessed for their attention and level of anxiety. Methylphenidate was administered for a week in a randomized double-blind drug/placebo-drug cross-over design. The levels of anxiety were evenly distributed between the inattentive and hyperactive/impulsive types. Anxiety was significantly correlated with the attention as reported by both teachers and parents. The response to methylphenidate was inversely correlated with the reported anxiety level only in boys with the hyperactive/impulsive and combined types. The higher the level of anxiety, the lower level of response to methylphenidate was observed. In the assessment and treatment of children with ADHD, the level of anxiety should be evaluated and taken into account while planning and monitoring treatment regiment.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22622628     DOI: 10.1007/s12402-012-0078-2

Source DB:  PubMed          Journal:  Atten Defic Hyperact Disord        ISSN: 1866-6116


  9 in total

1.  Genetic Variations in Elements of the Oxytocinergic Pathway are Associated with Attention/Hyperactivity Problems and Anxiety Problems in Childhood.

Authors:  Laísa Camerini; Gabriel Zurchimitten; Bertha Bock; Janaína Xavier; Clarissa Ribeiro Bastos; Evânia Martins; Ana Paula Ardais; Janaína Vieira Dos Santos Motta; Andressa Jacondino Pires; Mariana Bonati de Matos; Luciana de Ávila Quevedo; Ricardo Tavares Pinheiro; Gabriele Ghisleni
Journal:  Child Psychiatry Hum Dev       Date:  2022-09-10

2.  ADHD and Anxiety: Clinical Significance and Treatment Implications.

Authors:  Frederick W Reimherr; Barrie K Marchant; Thomas E Gift; Tammy A Steans
Journal:  Curr Psychiatry Rep       Date:  2017-11-20       Impact factor: 5.285

3.  Disentangling the autism-anxiety overlap: fMRI of reward processing in a community-based longitudinal study.

Authors:  N Mikita; E Simonoff; D S Pine; R Goodman; E Artiges; T Banaschewski; A L Bokde; U Bromberg; C Büchel; A Cattrell; P J Conrod; S Desrivières; H Flor; V Frouin; J Gallinat; H Garavan; A Heinz; B Ittermann; S Jurk; J L Martinot; M L Paillère Martinot; F Nees; D Papadopoulos Orfanos; T Paus; L Poustka; M N Smolka; H Walter; R Whelan; G Schumann; A Stringaris
Journal:  Transl Psychiatry       Date:  2016-06-28       Impact factor: 6.222

4.  Are psychiatric comorbidities and associated cognitive functions related to treatment response to methylphenidate in boys with attention-deficit/hyperactivity disorder?

Authors:  Mandy H Chan; Patrick Wl Leung; Ting-Pong Ho; Se-Fong Hung; Chi-Chiu Lee; Chun-Pan Tang; Ka-Chai Cheung; Fung-Yee Ching; Fefe Hk Chan; Lu-Hua Chen; Merce Garcia-Barcelo; Pak-Chung Sham
Journal:  Neuropsychiatr Dis Treat       Date:  2017-04-11       Impact factor: 2.570

5.  Psychiatric comorbid patterns in adults with attention-deficit hyperactivity disorder: Treatment effect and subtypes.

Authors:  Fang-Ju Tsai; Wan-Ling Tseng; Li-Kuang Yang; Susan Shur-Fen Gau
Journal:  PLoS One       Date:  2019-02-07       Impact factor: 3.240

6.  Stimulant treatment profiles predicting co-occurring substance use disorders in individuals with attention-deficit/hyperactivity disorder.

Authors:  Annabeth P Groenman; Lizanne J S Schweren; Wouter Weeda; Marjolein Luman; Siri D S Noordermeer; Dirk J Heslenfeld; Barbara Franke; Stephen V Faraone; Nanda Rommelse; Catharina A Hartman; Pieter J Hoekstra; Jan Buitelaar; Jaap Oosterlaan
Journal:  Eur Child Adolesc Psychiatry       Date:  2019-02-05       Impact factor: 4.785

7.  Methodological advantages and disadvantages of parallel and crossover randomised clinical trials on methylphenidate for attention deficit hyperactivity disorder: a systematic review and meta-analyses.

Authors:  Helle B Krogh; Ole Jakob Storebø; Erlend Faltinsen; Adnan Todorovac; Erica Ydedahl-Jensen; Frederik Løgstrup Magnusson; Mathilde Holmskov; Trine Gerner; Christian Gluud; Erik Simonsen
Journal:  BMJ Open       Date:  2019-03-30       Impact factor: 2.692

Review 8.  Methylphenidate for children and adolescents with attention deficit hyperactivity disorder (ADHD).

Authors:  Ole Jakob Storebø; Erica Ramstad; Helle B Krogh; Trine Danvad Nilausen; Maria Skoog; Mathilde Holmskov; Susanne Rosendal; Camilla Groth; Frederik L Magnusson; Carlos R Moreira-Maia; Donna Gillies; Kirsten Buch Rasmussen; Dorothy Gauci; Morris Zwi; Richard Kirubakaran; Bente Forsbøl; Erik Simonsen; Christian Gluud
Journal:  Cochrane Database Syst Rev       Date:  2015-11-25

9.  Clinical and Neuropsychological Predictors of Methylphenidate Response in Children and Adolescents with ADHD: A Naturalistic Follow-up Study in a Spanish Sample.

Authors:  María Vallejo-Valdivielso; Pilar de Castro-Manglano; Azucena Díez-Suárez; Juan J Marín-Méndez; Cesar A Soutullo
Journal:  Clin Pract Epidemiol Ment Health       Date:  2019-12-31
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.